Abstract
Imatinib mesylate is the first molecule of targeted therapy in chronic myelogenous leukaemia inhibiting constitutively activated BCR-ABL kinase. There are no long-term follow-up studies of large sample sizes to assess the toxicity of the use of imatinib mesylate over 10 years. Several cases of hepatotoxicity, including fatal liver failure, have been associated with the long-term use of imatinib mesylate. We report here on a patient who experienced immediate dominant cholestatic damage of the liver and mild hepatocyte damage during imatinib mesylate therapy. This differs from most reports showing dominantly acute hepatitis with necrosis associated with the use of imatinib mesylate.
Copyright 2007 S. Karger AG, Basel.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzamides
-
Bile Ducts / pathology
-
Blast Crisis / drug therapy*
-
Chemical and Drug Induced Liver Injury / etiology*
-
Cholestasis, Intrahepatic / chemically induced*
-
Cytarabine / administration & dosage
-
Drug Eruptions / etiology
-
Hepatocytes / pathology
-
Humans
-
Idarubicin / administration & dosage
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Liver Function Tests
-
Male
-
Middle Aged
-
Piperazines / administration & dosage
-
Piperazines / adverse effects*
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Pyrimidines / therapeutic use
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Cytarabine
-
Imatinib Mesylate
-
Idarubicin